Pharmaceuticals & Therapeutics

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

CEO Werner Lanthaler will present FairJourney Bio's data-driven antibody discovery platform at the elite J.P. Morgan conference, signaling major growth.

From AI-powered diagnostics to non-hallucinogenic psychedelics, 2025's discoveries are redefining mental healthcare and offering new hope.

As Harmony Biosciences presents at JPM, investors will scrutinize its strategy for sustaining growth beyond its star drug and advancing its rare disease pipeline.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

With $16.4M in new funding, STRM.BIO is advancing a novel gene therapy platform that uses natural vesicles to target bone marrow, offering new hope for rare diseases.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

Pharma giant Bayer partners with AI innovator Cradle, betting on generative AI to accelerate its biologics pipeline and reshape modern medicine.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

A new nationwide study reveals a massive gap in care for heart failure patients, costing lives and billions. Why are proven, cheap medications being overlooked?

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

With a major new facility planned and a dynamic market, all eyes are on Clean Harbors as it prepares to address investors at two key January events.